Hexima Limited (HXL) is a biotechnology company actively engaged in the research and development of plant-derived defensin peptides for applications as human therapeutics. Hexima's lead drug candidate is the plant defensin, pezadeftide (formerly HXP124), which is being developed for treatment of fungal nail infections (onychomycosis). Hexima is conducting a phase IIb clinical trial at 15 sites in Australia and New Zealand. The trial has enrolled 117 patients with onychomycosis and seeks to identify the optimal course of therapy for pezadeftide.
Contact Details
Level 4
,
LIMS2, Kingsbury Dr
LA TROBE UNIVERSITY
VIC
3086
03 9479 1210
info@hexima.com.au
